-
21.发明公开
公开(公告)号：EP2654793A4
公开(公告)日：2015-07-22
申请号：EP11852145
申请日：2011-12-21
申请人： LEIDOS INC
发明人： DRESIOS JOHN , GRIFFEY RICHARD
IPC分类号： A61K39/44 , G01N33/50 , G01N33/567
CPC分类号： G01N33/6887 , A61K9/1271 , A61K38/02 , A61K38/1777 , A61K39/44 , A61K47/42 , A61K47/48376 , A61K47/48384 , A61K47/48415 , A61K47/48553 , A61K47/6801 , A61K47/6803 , A61K47/6811 , A61K47/6847 , A61K49/0058 , C07K16/18 , G01N33/5088 , G01N33/567 , G01N33/6893 , G01N2333/47 , G01N2333/4712 , G01N2333/78
摘要： The present disclosure relates to methods for identifying proteins or peptide motifs of intracellular, extracellular, or extracellular matrix proteins specifically exposed in wound sites, as well as compositions for treating wounds, and methods for their use.
摘要翻译： 本公开涉及用于鉴定特异性暴露于伤口部位的细胞内，细胞外或细胞外基质蛋白的蛋白质或肽基序的方法，以及用于治疗伤口的组合物及其使用方法。
-
公开(公告)号：EP2575883A2
公开(公告)日：2013-04-10
申请号：EP11790443.3
申请日：2011-06-03
IPC分类号： A61K39/395 , C12N15/113
CPC分类号： A61K39/3955 , A61K31/7088 , A61K31/713 , A61K38/1777 , A61K45/06 , A61K2300/00
摘要： A method is provided for treating certain inflammatory disorders by inhibiting cadherin-11 function using a cadherin-11 antagonist.
-
公开(公告)号：EP1294391B1
公开(公告)日：2012-08-15
申请号：EP01942118.9
申请日：2001-06-08
IPC分类号： A61K38/17 , A61K39/395 , C07K16/28 , A61P37/06
CPC分类号： C07K16/2845 , A61K38/1709 , A61K38/1774 , A61K38/1777 , A61K45/06 , A61K2039/505 , C07K16/2875 , C07K2319/00 , C07K2319/30 , A61K2300/00
摘要： The invention provides methods for regulating cell-mediated immune responses, immune system diseases and allograft transplant rejection by interfering with the interaction of at least three different cell surface molecules with their natural ligands. A first cellular interaction is mediated by CD28/B7/CTLA4, a second interaction is mediated by CD40/CD154, and a third interaction is mediated by LFA-1 interaction with its ligands. Regulation of a cell-mediated immune response affects immune system diseases such as those associated with allograft transplantation.
-
24.发明公开PROLIFERATION-ASSOCIATED MODULATION OF THE SPLICING OF THE INTEGRIN ALPHA 6 ISOFORMS 有权整联ALPHA-6-异构体增殖相关调制剪接
公开(公告)号：EP2370109A1
公开(公告)日：2011-10-05
申请号：EP09831355.4
申请日：2009-12-10
IPC分类号： A61K48/00 , A61K31/7088 , A61K38/17 , A61K45/00 , A61P35/00 , C12Q1/68 , G01N33/567 , G01N33/574 , G01N33/68 , C12N15/63 , C12N15/85
CPC分类号： C12N15/87 , A61K31/00 , A61K31/7088 , A61K38/1777 , C12N15/113 , C12N2310/14 , C12N2799/027 , G01N33/574 , G01N2333/70546
摘要： This application relates to the use of agents such as expression vectors and nucleic acids encoding integrins α6 A or α6B as well as antibodies specific for those integrins which are capable of modulating the ratio between the B and A isoforms of the α6 integrin in the treatment of diseases associated with an altered proliferation rate, such as cancer. The application also relates to the use of the ratio between the B and A isoforms of the α6 integrin in the diagnosis of diseases associated with an altered proliferation rate.
-
25.发明公开
公开(公告)号：EP1328298A1
公开(公告)日：2003-07-23
申请号：EP01981352.6
申请日：2001-10-02
IPC分类号： A61K48/00
CPC分类号： A61K38/1777 , A61K38/177 , A61K38/1774 , A61K48/00 , A61K2039/505 , C07K16/2803 , A61K2300/00
摘要： This invention relates generally to the field of immunology or neuroimmunology. In particular, the invention provides a method for reducing or inhibiting T cell activation, which method comprises administering an effective amount of an antagonist of NCAM L1 to a mammal, wherein reduction or inhibition of T cell activation is desirable, thereby reducing or inhibiting T cell activation in said mammal. Combinations and combinatorial methods for modulating T cell activation are further provided. The invention also provides a method for potentiating T cell activation, which method comprises administering an effective amount of a multimerized neural cell adhesion molecule L1 (NCAM L1), or a functional derivative or fragment thereof, or a nucleic acid encoding said L1 or func tional derivative or fragment thereof, or an agent that enhances production and/or costimulatory function of said L1 to a mammal, wherein T cell activation is desirable, thereby potentiating T cell activation in said mammal.
-
26.发明公开
公开(公告)号：EP1124572A2
公开(公告)日：2001-08-22
申请号：EP99970605.4
申请日：1999-10-22
申请人： Curagen Corporation
IPC分类号： A61K38/43 , A61K38/21 , A61K38/17 , A61K48/00 , A61K39/395 , G01N33/50 , C12Q1/70 , C12N15/12 , C12N15/52 , A61P13/12 , A01K67/027
CPC分类号： G01N33/5091 , A01K2217/052 , A01K2267/03 , A61K38/1709 , A61K38/1748 , A61K38/177 , A61K38/1777 , A61K38/215 , A61K38/44 , A61K38/45 , A61K38/46 , A61K38/4813 , A61K38/4853 , A61K38/57 , A61K45/06 , A61K2039/505 , C12Y304/11002 , G01N33/5008 , G01N33/502 , G01N33/5023 , A61K2300/00
摘要： The present invention discloses 16 genes that are differentially expressed in animal models of hypertension relative to non-hypertensive controls. In particular, 16 genes were identified which are differentially-expressed in the fawn-hooded rat (FHR) and the closely-related IRL rat strain, in comparison to the control ACI strain of rat. Also disclosed are therapeutic and prophylactic methods for treating or preventing renal failure, platelet storage-pool disease, hypertension, insulin-dependent diabetes mellitus (IDDM) and/or other associated diseases or disorders using these genes and nucleic acids encoding these genes. Methods for diagnosis, prognosis, and screening, by the detection of the differentially-expressed proteins and nucleic acids, as well as derivatives, fragments and analogs thereof, are also disclosed herein.
-
公开(公告)号：EP0462205A4
公开(公告)日：1992-01-15
申请号：EP90905066
申请日：1990-03-09
CPC分类号： A61K38/1777 , A61K38/1774 , A61K2300/00
摘要： This invention concerns the cloning of the alpha-subunit of the p150,95 leukocyte adhesion receptor molecule. The invention also concerns the alpha-subunit of p150,95, as well as fragments of this receptor molecule. The invention further pertains to the diagnostic and therapeutic uses for such molecules.
-
公开(公告)号：EP0462205A1
公开(公告)日：1991-12-27
申请号：EP90905066.0
申请日：1990-03-09
CPC分类号： A61K38/1777 , A61K38/1774 , A61K2300/00
摘要： L'invention concerne le clonage de la sous-unité alpha de la molécule réceptrice d'adhérence du leucocyte p150,95. L'invention concerne également la sous-unité alpha de p150,95, ainsi que des fragments de cette molécule réceptrice. Elle concerne en outre les emplois diagnostiques et thérapeutiques desdites molécules.
摘要翻译： 本发明涉及克隆白细胞粘附受体分子p150,95的α亚基。 本发明还涉及p150,95的α亚基以及该受体分子的片段。 它还涉及所述分子的诊断和治疗用途。
-
公开(公告)号：EP0462184A1
公开(公告)日：1991-12-27
申请号：EP90904579.0
申请日：1990-03-09
CPC分类号： A61K38/1774 , A61K38/1777 , A61K2300/00
摘要： L'invention concerne une sous-unité beta de recombinaison sensiblement pure d'une glycoprotéine humaine relative à l'adhérence cellulaire, ou une fraction biologiquement active, un analogue ou un fragment de celle-ci, composé d'au moins 10 % d'une séquence contiguë de la sous-unité beta, une séquence d'ADNc codante à cet effet, ainsi qu'un vecteur contenant une séquence d'ADN codante à cet effet. L'invention concerne également tout anticorps monoclonal développé contre la sous-unité beta de LFA-1 humaine, ainsi qu'un procédé de traitement d'infections rhinovirales à l'aide de LFA-1.
-
公开(公告)号：EP3263121A1
公开(公告)日：2018-01-03
申请号：EP17184825.2
申请日：2011-12-21
申请人： Leidos, Inc.
发明人： DRESIOS, John , GRIFFEY, Richard
IPC分类号： A61K38/02 , G01N33/50 , G01N33/567
CPC分类号： G01N33/6887 , A61K9/1271 , A61K38/02 , A61K38/1777 , A61K39/44 , A61K47/42 , A61K47/6801 , A61K47/6803 , A61K47/6811 , A61K47/6847 , A61K49/0058 , C07K16/18 , G01N33/5088 , G01N33/567 , G01N33/6893 , G01N2333/47 , G01N2333/4712 , G01N2333/78
摘要： The present disclosure relates to methods for identifying proteins or peptide motifs of intracellular, extracellular, or extracellular matrix proteins specifically exposed in wound sites, as well as compositions for treating wounds, and methods for their use.
摘要翻译： 本公开涉及用于鉴定在伤口部位特异性暴露的细胞内，细胞外或细胞外基质蛋白质的蛋白质或肽基序的方法，以及用于治疗伤口的组合物，以及它们的使用方法。
-
-
-
-
-
-
-
-
-
搜索结果
40 条记录 (耗时 0.03 秒)
